Serological Cytokine Signature in Paediatric Patients with Inflammatory Bowel Disease Impacts Diagnosis

1. Braegger, C. P. et al. Epidemiology of inflammatory bowel disease: is there a shift towards onset at a younger age?. J. Pediatr. Gastroenterol. Nutr. 53, 141–144 (2011).

2. Gismera, C. S. & Aladren, B. S. Inflammatory bowel diseases: A disease (s) of modern times? Is incidence still increasing?. World

J. Gastroenterol. 14, 5491–5498 (2008).

3. Kugathasan, S. et al. Wisconsin pediatric inflammatory bowel disease alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr. 143, 525–531

(2003).

4. Lakatos, P. L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J. Gastroenterol. 12, 6102–6108

(2006).

5. Ishige, T. et al. Temporal trend of pediatric inflammatory bowel disease: Analysis of national registry data 2004 to 2013 in Japan.

J. Pediatr. Gastroenterol. Nutr. 65, 80–82 (2017).

6. Henderson, P. et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm. Bowel Dis. 18, 999–1005 (2012).

7. Ashton, J. J. et al. Rising incidence of paediatric inflammatory bowel disease (PIBD) in Wessex, Southern England. Arch. Dis. Child.

99, 659–664 (2014).

8. Malmborg, P. et al. Presentation and progression of childhood-onset inflammatory bowel disease in Northern Stockholm County.

Inflamm. Bowel Dis. 21, 1098–1108 (2015).

9. Van Limbergen, J. et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology

135, 1114–1122 (2008).

10. Gower-Rousseau, C. et al. The natural history of pediatric ulcerative colitis: A population-based cohort study. Am J. Gastroenterol.

104, 2080–2088 (2009).

11. Vernier-Massouille, G. et al. Natural history of pediatric Crohn’s disease: A population-based cohort study. Gastroenterology 135,

1106–1113 (2008).

12. Pigneur, B. et al. Natural history of Crohn’s disease: Comparison between childhood- and adult-onset disease. Inflamm. Bowel Dis

16, 953–961 (2010).

13. Sankey, E. A. et al. Early mucosal changes in Crohn’s disease. Gut 34, 375–381 (1993).

14. Moum, B., Ekbom, A., Vatn, M. H. & Elgjo, K. Change in the extent of colonoscopic and histological involvement in ulcerative

colitis over time. Am. J. Gastroenterol. 94, 1564–1569 (1999).

15. Levine, A. et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification.

Inflamm. Bowel Dis. 17, 1314–1321 (2011).

16. Bhattacharya, P. et al. Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: Implications for immune therapy.

J. Interferon Cytokine Res. 35, 585–599 (2015).

17. Dabritz, J. et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel

disease. Am. J. Gastroenterol. 108, 1901–1910 (2013).

18. Wine, E. et al. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.

J. Crohns Colitis. 7, 916–922 (2013).

19. Hyams, J. et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children.

Gastroenterology 132, 863–873 (2007).

20. Fujitake, Y. et al. Analysis of inflammatory signals in Japanese children with Crohn’s disease. Pediatr. Int. 55, 753–756 (2013).

21. Ohtani, K. et al. Increased mucosal expression of GATA-3 and STAT-4 in pediatric ulcerative colitis. Pediatr. Int. 52, 584–589

(2010).

22. Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: The SES-CD.

Gastrointest. Endosc. 60, 505–512 (2004).

23. Travis, S. P. et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 145,

987–995 (2013).

24. Korolkova, O. Y., Myers, J. N., Pellom, S. T., Wang, L. & M’Koma, A. E. Characterization of serum cytokine profile in predominantly

colonic inflammatory bowel disease to delineate ulcerative and Crohn’s colitides. Clin. Med. Insights Gastroenterol. 8, 29–44 (2015).

25. Kader, H. A. et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated

serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn’s disease and ulcerative colitis patients in remission versus active

disease. Am. J. Gastroenterol. 100, 414–423 (2005).

26. Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330–342

(2011).

27. Watanabe, M. et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in

the colonic mucosa. J. Exp. Med. 187, 389–402 (1998).

28. Yamazaki, M. et al. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J.

Immunol. 171, 1556–1563 (2003).

29. Belarif, L. et al. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J. Clin.

Invest. 129, 1910–1925 (2019).

30. Andreu-Ballester, J. C. et al. Deficit of interleukin-7 in serum of patients with Crohn’s disease. Inflamm. Bowel Dis. 19, E30-31

(2013).

31. Fagan, E. A. et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur. J. Clin. Invest. 12, 351–359 (1982).

32. Torres, J. et al. Serum Biomarkers identify patients who will develop inflammatory bowel diseases up to 5 y before diagnosis.

Gastroenterology. https​://doi.org/10.1053/j.gastr​o.2020.03.007 (2020)

33. Carman, N. et al. Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn’s

disease. Gastrointest. Endosc. 89, 364–372 (2019).

34. Oliva, S. et al. Endoscopy in pediatric inflammatory bowel disease: A position paper on behalf of the porto IBD Group of the

European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 67, 414–430 (2018).

Scientific Reports |

Vol:.(1234567890)

(2020) 10:14638 |

https://doi.org/10.1038/s41598-020-71503-y

10

www.nature.com/scientificreports/

35. Caviglia, G.P. et al. On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients

with inflammatory bowel diseases. J. Clin. Med. 9, 800, https​://doi.org/10.3390/jcm90​30800​ (2020).

36. Rothschild, B. et al. Prognostic significance of granulomas in children with Crohn’s disease. Scand. J. Gastroenterol. 52, 716–721

(2017).

37. Maisawa, S. et al. Characteristics of inflammatory bowel disease with an onset before eight years of age: A multicenter epidemiological survey in Japan. J. Gastroenterol. Hepatol. 28, 499–504 (2013).

38. Levine, A. et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J.

Pediatr. Gastroenterol. Nutr. 58, 795–806 (2014).

39. Eszter Müller, K., Laszlo Lakatos, P., Papp, M. & Veres, G. Incidence and Paris classification of pediatric inflammatory bowel

disease. Gastroenterol. Res. Pract. 2014, 904307 (2014).

40. Hyams, J. S. et al. Development and validation of a pediatric Crohn’s disease activity index. J. Pediatr. Gastroenterol. Nutr. 12,

439–447 (1991).

41. Turner, D. et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: A prospective multicenter

study. Gastroenterology 133, 423–432 (2007).

Acknowledgements

The authors would like to thank all participating patients and their families for their cooperation. We would

also like to thank Ms. Kiyoe Ishii for providing technical assistance and Editage (https​://www.edita​ge.com) for

English language editing.

Author contributions

R.H., T.I., T.N., and M.T. contributed to the conception and design of this study. M.T. performed the statistical

analyses and drafted the manuscript. S.K. and T.H. provided specimens. H.A., T.T., and T.T. critically reviewed

the manuscript and supervised the whole study process. All authors read and approved the final manuscript.

Competing interests The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https​://doi.org/10.1038/s4159​8-020-71503​-y.

Correspondence and requests for materials should be addressed to T.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and

institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the

Creative Commons licence, and indicate if changes were made. The images or other third party material in this

article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the

material. If material is not included in the article’s Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from

the copyright holder. To view a copy of this licence, visit http://creat​iveco​mmons​.org/licen​ses/by/4.0/.

© The Author(s) 2020

Scientific Reports |

(2020) 10:14638 |

https://doi.org/10.1038/s41598-020-71503-y

11

Vol.:(0123456789)

...